Fiduciary Family Office LLC Invests $1.51 Million in Johnson & Johnson (NYSE:JNJ)

Key Points

• Fiduciary Family Office LLC has invested approximately $1.51 million in Johnson & Johnson by purchasing 9,092 shares, according to its recent SEC filing.
• Johnson & Johnson reported $2.77 EPS for the last quarter, surpassing analyst expectations and showing a 5.8% year-over-year revenue increase.
• The company will pay a quarterly dividend of $1.30 per share on September 9th, representing an annualized rate of $5.20 and a yield of 3.0%.

Fiduciary Family Office LLC purchased a new position in Johnson & Johnson (NYSE:JNJ - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,092 shares of the company's stock, valued at approximately $1,508,000.

A number of other hedge funds have also recently made changes to their positions in JNJ. Highline Wealth Partners LLC grew its holdings in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares during the last quarter. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson in the first quarter worth about $49,000. Capital A Wealth Management LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth about $50,000. Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the first quarter worth about $52,000. Finally, Accredited Wealth Management LLC bought a new position in Johnson & Johnson during the 4th quarter worth about $58,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $173.40 on Friday. The firm has a market capitalization of $417.61 billion, a P/E ratio of 18.55, a PEG ratio of 2.18 and a beta of 0.41. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company has a 50 day moving average price of $159.26 and a 200 day moving average price of $157.44. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $173.96.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's revenue was up 5.8% on a year-over-year basis. During the same period last year, the firm posted $2.82 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Analysts Set New Price Targets

Several brokerages have issued reports on JNJ. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Royal Bank Of Canada increased their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. UBS Group increased their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Finally, Raymond James Financial dropped their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Nine analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.